Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

None of this is surprising — especially when at least 500,000 Brits are currently taking Mounjaro and Wegovy via private prescription. For many, the prospect of going cold turkey or forking out up to ...

Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...